# AAVantgarde funding rounds and investors

As of 14 Oct 2026, AAVantgarde has raised $141M across 1 verified round on record; latest: $141 million (€122 million) Series B led by Schroders Capital, announced 3 Nov 2025.

AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet need

Website: https://aavantgarde.com  
Page: https://fireround.dev/companies/aavantgarde.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-11-03 | Series B | $141 million (€122 million) | Schroders Capital | Amgen Ventures, Athos Capital, Atlas Ventures, CDP Venture Capital through its Large Ventures Fund, Columbia IMC, Forbion, Longwood Fund, Neva SGR (Intesa Sanpaolo Bank), Sixty Degree Capital, Sofinnova Partners, Willett Advisors, XGEN Venture | [globenewswire.com](https://www.globenewswire.com/news-release/2025/11/03/3178907/0/en/AAVantgarde-Closes-141-Million-Series-B-Financing-to-Advance-its-Clinical-Programs-in-Stargardt-Disease-and-Usher-1B-Syndrome.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.